55040-34-1

Usage

Uses

Not much is known about the specific applications of 4-hydroxythieno[3,2-c]pyridine-7-carbonitrile. However, given its classification as a Thienopyridine, it is likely to have potential uses in various fields, such as:
Used in Pharmaceutical Industry:
4-hydroxythieno[3,2-c]pyridine-7-carbonitrile could be used as a pharmaceutical compound for its potential biological activity. The presence of the heterocyclic thienopyridine core may allow it to interact with biological targets, making it a candidate for drug development.
Used in Chemical Research:
4-hydroxythieno[3,2-c]pyridine-7-carbonitrile may serve as a research compound in the field of organic chemistry, particularly in the study of Thienopyridines. Its unique structure could provide insights into the properties and reactivity of this class of compounds.
Used in Material Science:
4-hydroxythieno[3,2-c]pyridine-7-carbonitrile might also find applications in material science, where its structural features could be exploited to develop new materials with specific properties, such as electronic or optical characteristics.

Upstream product

• 544-92-3 copper(I) cyanide 
• 29079-94-5 7-bromothieno[3,2-c]pyridine-4(5H)-one 
• 912368-69-5 (2Z)-3-cyano-3-(2-thienyl)acryloyl azide 
• 20893-30-5 2-cyanomethylthiophene 
• 912368-67-3 (2Z)-3-cyano-3-(2-thienyl)acrylic acid potassium salt 
• 912368-68-4 (2Z)-3-cyano-3-(2-thienyl)acryloyl chloride 

Downstream Products

• 55040-43-2 2-bromo-4-oxo-4,5-dihydrothieno[3,2-c]pyridine-7-carbonitrile 
• 1261302-02-6 4-chlorothieno[3,2-c]pyridine-7-carbonitrile 
• 912369-04-1 4-{[(3S)-1-methylpiperidin-3-yl]amino}-2-phenylthieno[3,2-c]pyridine-7-carbonitrile 

Relevant academic research and scientific papers

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors

A novel series of CHK1 inhibitors based on thienopyridine template has been designed and synthesized. These inhibitors maintain critical hydrogen bonding with the hinge and conserved water in the ATP binding site. Several compounds show single digit nanomolar CHK1 activities. Compound 70 shows excellent enzymatic activity of 1 nM.

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

THIENOPYRIDINES AS IKK INHIBITORS

The invention is concerned with a compound of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein A, W, X, Y, Z and R1 are as defined in the description and the claims. These compounds inhibit IKK and can be

Antiinflammation agents

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.